VCP and plasma cell myeloma: Previous studies have indicated that VCP inhibition decreased the survival of multiple cancer cell lines: CB-5083 has been reported to diminish cell survival of human multiple myeloma [11], human acute lymphoblastic leukemia [12] and human mantle cell lymphoma [14].